For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220411:nRSK8729Ha&default-theme=true
RNS Number : 8729H Sareum Holdings PLC 11 April 2022
Sareum Holdings plc
("Sareum" or the "Company")
European Patent Granted for Sareum's SDC-1802, a Novel Small Molecule
TYK2/JAK1 Inhibitor, for the Treatment of T-cell Acute Lymphoblastic Leukaemia
Cambridge, UK, 11 April 2022 - Sareum Holdings plc (AIM: SAR), the specialist
drug development company, announces that, further to its announcement on 15
December 2021, the European Patent Office has now issued a formal notification
of grant for a patent in respect of an invention associated with Sareum's
proprietary SDC-1802 TYK2/JAK1 inhibitor programme. The patent will come into
effect on 4 May 2022.
The patent (EPO Patent no. EP3528806) will protect the SDC-1802 molecule and
pharmaceutical preparations thereof as a therapeutic to treat T-cell acute
lymphoblastic leukaemia (T-ALL - a cancer of a particular type of white blood
cell called a T lymphocyte) and other cancers that are dependent on TYK2
kinase for survival. This programme is in preclinical development.
Sareum's CSO, Dr John Reader, commented:
"This newly issued European patent for SDC-1802 expands our already broad and
robust patent portfolio covering both our novel TYK2/JAK1 inhibitor candidates
and further supports their commercial potential as new treatments for
autoimmune diseases and cancer. Building a strong intellectual property
portfolio around our TYK2/JAK1 assets is a core strategic focus for Sareum
that we believe is creating important value for our shareholders."
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO 01223 497700
Strand Hanson Limited (Nominated Adviser)
James Dance / James Bellman 020 7409 3494
Peel Hunt LLP (Joint Corporate Broker)
James Steel 020 7418 8900
Hybridan LLP (Joint Corporate Broker)
Claire Noyce 020 3764 2341
MEDiSTRAVA Consulting (Financial PR)
Mark Swallow / George Underwood / Evelyn McCormack 020 3928 6900
About Sareum
Sareum is a specialist drug development company delivering targeted small
molecule therapeutics to improve the treatment of cancer and autoimmune
diseases. The Company aims to generate value through licensing its candidates
to international pharmaceutical and biotechnology companies at the preclinical
or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine
kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical
development as therapies for autoimmune diseases, including the 'cytokine
storm' immune system overreaction to Covid-19 and other viral infections,
(SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral,
selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell
replication and DNA damage repair mechanisms. Preliminary Phase 2 and
comprehensive preclinical data suggest SRA737 may have broad application in
combination with other oncology and immune-oncology drugs in genetically
defined patients.
SRA737 was discovered and initially developed by scientists at The Institute
of Cancer Research in collaboration with Sareum, and with funding from Sareum
and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to
Sierra Oncology Inc. Sierra continues to explore options that would enable the
development of SRA737 to advance.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange,
trading under the ticker SAR. For further information, please visit the
Company's website at www.sareum.com (http://www.sareum.com)
- Ends -
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END MSCFLFIVSRIAIIF